See more : Metallus Inc. (MTUS) Income Statement Analysis – Financial Results
Complete financial analysis of Adhera Therapeutics, Inc. (ATRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Adhera Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- ArcelorMittal S.A. (MT.AS) Income Statement Analysis – Financial Results
- LiveWire Ergogenics, Inc. (LVVV) Income Statement Analysis – Financial Results
- Chorus Limited (CHRUF) Income Statement Analysis – Financial Results
- Zinnwald Lithium Plc (ZNWD.L) Income Statement Analysis – Financial Results
- Conifer Holdings, Inc. (CNFR) Income Statement Analysis – Financial Results
Adhera Therapeutics, Inc. (ATRX)
About Adhera Therapeutics, Inc.
Adhera Therapeutics, Inc. focuses on the discovery and development of drugs. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 252.00K | 76.19K | 0.00 | 0.00 | 680.00K | 500.00K | 2.12M | 4.22M | 2.24M | 2.46M | 14.73M | 2.61M | 18.14M | 28.49M | 7.45M | 1.85M | 19.44M | 8.92M | 2.60M | 4.14M | 4.50M | 8.10M | 4.10M | 0.00 | 2.90M | 2.10M | 860.00K | 320.00K | 760.00K | 1.19M | 640.00K | 360.00K | 590.00K | 20.00K |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 409.00K | 458.71K | 450.90K | 49.19K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.91M | 100.00K | 355.00K | 21.00K | 258.00K | 498.00K | 289.00K | 503.00K | -374.00K | -100.00K | 300.00K | 200.00K | 0.00 | 0.00 | 1.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | -157.00K | -382.52K | -450.90K | -49.19K | 680.00K | 500.00K | 2.12M | 4.22M | 2.24M | 2.46M | 14.73M | -297.00K | 18.04M | 28.14M | 7.43M | 1.59M | 18.94M | 8.63M | 2.10M | 4.52M | 4.60M | 7.80M | 3.90M | 0.00 | 2.90M | 1.10M | 860.00K | 320.00K | 760.00K | 1.19M | 640.00K | 360.00K | 590.00K | 20.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | -62.30% | -502.09% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | -11.38% | 99.45% | 98.75% | 99.72% | 86.03% | 97.44% | 96.76% | 80.68% | 109.03% | 102.22% | 96.30% | 95.12% | 0.00% | 100.00% | 52.38% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 240.98K | 907.49K | 108.86K | 801.00K | 686.00K | 715.00K | 5.17M | 11.44M | 18.11M | 14.88M | 36.77M | 52.25M | 43.24M | 30.33M | 21.08M | 17.10M | 11.42M | 7.33M | 7.33M | 9.60M | 6.00M | 4.60M | 0.00 | 900.00K | 500.00K | 440.00K | 400.00K | 310.00K | 540.00K | 430.00K | 530.00K | 570.00K | 350.00K |
| General & Administrative | 1.62M | 657.00K | 1.20M | 4.71M | 6.03M | 4.73M | 599.68K | 3.87M | 3.33M | 1.77M | 0.00 | 0.00 | 0.00 | 0.00 | 12.03M | 17.92M | 12.28M | 9.57M | 8.14M | 5.68M | 8.80M | 4.32M | 6.79M | 4.10M | 3.90M | 5.00M | 0.00 | 2.10M | 400.00K | 200.00K | 230.00K | 830.00K | 890.00K | 750.00K | 840.00K | 1.08M | 860.00K |
| Selling & Marketing | 0.00 | 17.00K | 839.00K | 5.26M | 3.64M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.59M | 2.39M | 1.93M | 1.33M | 1.86M | 2.38M | 1.39M | 953.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.62M | 674.00K | 2.04M | 9.97M | 9.67M | 4.73M | 599.68K | 3.87M | 3.33M | 1.77M | 5.25M | 8.37M | 10.36M | 10.09M | 13.62M | 20.31M | 14.21M | 10.90M | 9.00M | 8.06M | 10.20M | 4.32M | 6.79M | 4.10M | 3.90M | 5.00M | 0.00 | 2.10M | 400.00K | 200.00K | 230.00K | 830.00K | 890.00K | 750.00K | 840.00K | 1.08M | 860.00K |
| Other Expenses | 0.00 | -141.00K | 45.00K | 70.00K | -810.22K | 450.90K | 49.19K | 0.00 | 0.00 | 0.00 | 1.68M | 17.42M | 3.53M | 455.00K | 8.26M | 0.00 | 0.00 | 0.00 | 604.00K | 0.00 | 604.00K | 487.00K | 732.00K | 400.00K | 300.00K | 300.00K | 0.00 | 0.00 | 0.00 | 320.00K | 0.00 | 70.00K | 120.00K | 90.00K | 90.00K | 90.00K | 100.00K |
| Operating Expenses | 1.62M | 674.00K | 2.04M | 10.04M | 10.24M | 6.09M | 757.73K | 4.67M | 4.02M | 2.48M | 10.42M | 19.81M | 28.46M | 24.97M | 50.39M | 72.57M | 57.45M | 41.23M | 30.08M | 25.15M | 21.62M | 11.65M | 14.85M | 14.10M | 10.20M | 9.90M | 0.00 | 3.00M | 900.00K | 960.00K | 630.00K | 1.21M | 1.55M | 1.27M | 1.46M | 1.74M | 1.31M |
| Cost & Expenses | 1.62M | 674.00K | 2.04M | 10.45M | 10.70M | 6.09M | 757.73K | 4.67M | 4.02M | 2.48M | 10.42M | 19.81M | 28.46M | 24.97M | 53.29M | 72.67M | 57.81M | 41.25M | 30.34M | 25.65M | 21.91M | 12.16M | 14.48M | 14.00M | 10.50M | 10.10M | 0.00 | 3.00M | 1.90M | 960.00K | 630.00K | 1.21M | 1.55M | 1.27M | 1.46M | 1.74M | 1.31M |
| Interest Income | 3.15K | 1.43K | 1.77K | 662.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 244.00K | 5.00K | 519.00K | 3.31M | 2.79M | 1.99M | 344.00K | 227.00K | 278.00K | 322.00K | 644.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 3.15M | 1.43M | 1.77M | 662.00K | 149.90K | 127.93K | 3.51K | 1.00K | 1.01M | 249.00K | 1.72M | 10.71M | 2.81M | 538.00K | 797.00K | 1.15M | 640.00K | 352.00K | 462.00K | 393.00K | 162.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -80.00K | -100.00K | -110.00K | -80.00K | 10.00K | 10.00K | 50.00K | 140.00K |
| Depreciation & Amortization | 0.00 | 674.00K | 82.00K | 82.00K | 332.99K | 450.90K | 49.19K | 1.11K | 0.00 | 0.00 | 555.00K | 1.25M | 1.58M | 2.37M | 4.11M | 4.39M | 2.90M | 1.83M | 1.44M | 1.41M | 1.40M | 846.00K | 732.00K | 400.00K | 300.00K | 300.00K | 0.00 | 0.00 | -100.00K | 30.00K | 30.00K | 100.00K | 110.00K | 80.00K | 20.00K | 100.00K | 280.00K |
| EBITDA | -1.62M | 0.00 | -1.99M | -11.23M | -16.27M | -5.64M | -708.54K | -3.99M | -5.47M | -1.36M | -7.24M | -27.03M | -23.37M | -7.87M | -46.57M | -50.14M | -26.41M | -31.97M | -26.70M | -4.80M | -11.59M | -8.71M | -9.60M | -9.05M | -2.05M | -5.70M | 0.00 | -100.00K | 100.00K | -230.00K | -480.00K | -570.00K | -410.00K | -540.00K | -1.08M | -1.05M | -1.01M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -4,015.08% | -14,564.82% | 0.00% | 0.00% | -586.62% | -704.00% | -17.26% | -145.22% | -729.87% | -1,025.93% | -71.91% | -1,468.53% | -276.45% | -92.71% | -429.17% | -1,464.43% | -46.47% | -123.19% | -334.54% | -231.90% | -202.22% | -43.21% | -173.17% | 0.00% | -3.45% | 4.76% | -26.74% | -150.00% | -75.00% | -34.45% | -84.38% | -300.00% | -177.97% | -5,050.00% |
| Operating Income | -1.62M | -674.00K | -2.04M | -11.32M | -15.79M | -6.09M | -757.73K | -3.99M | -3.52M | -365.00K | -7.88M | -35.00M | -29.53M | -10.69M | -58.94M | -54.53M | -29.32M | -33.80M | -28.49M | -6.21M | -13.58M | -9.55M | -10.34M | -9.50M | -2.40M | -6.00M | 0.00 | -100.00K | 200.00K | -260.00K | -510.00K | -670.00K | -520.00K | -620.00K | -1.10M | -1.15M | -1.29M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -4,490.48% | -20,731.94% | 0.00% | 0.00% | -586.62% | -704.00% | -17.26% | -186.93% | -1,565.07% | -1,200.41% | -72.58% | -2,259.18% | -300.66% | -102.90% | -453.77% | -1,542.56% | -31.95% | -152.24% | -367.04% | -249.58% | -211.11% | -29.63% | -146.34% | 0.00% | -3.45% | 9.52% | -30.23% | -159.38% | -88.16% | -43.70% | -96.88% | -305.56% | -194.92% | -6,450.00% |
| Total Other Income/Expenses | -496.00K | -5.68M | -1.73M | -662.00K | -959.96K | -127.93K | -78.61K | 7.33M | -2.96M | -1.25M | -1.62M | 6.71M | 1.78M | 2.65M | -278.00K | 2.16M | 2.15M | 1.64M | -118.00K | 4.24M | 116.00K | 322.00K | 0.00 | 0.00 | 1.35M | 1.40M | 0.00 | 100.00K | 100.00K | 80.00K | 100.00K | 110.00K | 80.00K | -10.00K | 10.00K | 50.00K | 140.00K |
| Income Before Tax | -2.11M | -6.35M | -3.77M | -11.98M | -16.75M | -6.22M | -836.34K | 3.34M | -6.48M | -1.61M | -9.51M | -28.28M | -25.19M | -7.51M | -67.20M | -52.37M | -26.88M | -32.16M | -13.47M | -1.98M | -13.58M | -9.23M | 0.00 | 0.00 | -1.00M | -4.60M | 0.00 | 0.00 | 300.00K | -180.00K | -410.00K | -560.00K | -440.00K | -630.00K | -1.09M | -1.10M | -1.15M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -4,753.17% | -21,992.17% | 0.00% | 0.00% | 490.74% | -1,295.40% | -76.12% | -225.44% | -1,264.80% | -1,023.98% | -51.00% | -2,575.66% | -288.76% | -94.34% | -431.78% | -729.18% | -10.16% | -152.24% | -354.67% | 0.00% | 0.00% | -12.35% | -112.20% | 0.00% | 0.00% | 14.29% | -20.93% | -128.13% | -73.68% | -36.97% | -98.44% | -302.78% | -186.44% | -5,750.00% |
| Income Tax Expense | 0.00 | 1.43M | 1.77M | 662.00K | 5.18M | 800.00 | 800.00 | -7.33M | 1.95M | -39.00K | 39.00K | 1.14M | -1.87M | -5.46M | 16.00M | -3.31M | -3.08M | -1.99M | -344.00K | -8.70M | 912.00K | -322.00K | -644.00K | -1.10M | -2.90M | -2.90M | 0.00 | 100.00K | 100.00K | -80.00K | -100.00K | -110.00K | -80.00K | 10.00K | -20.00K | -100.00K | -280.00K |
| Net Income | -2.11M | -7.78M | -5.54M | -12.64M | -16.75M | -6.22M | -837.14K | 3.34M | -6.48M | -1.57M | -9.55M | -29.42M | -27.75M | -8.05M | -59.22M | -52.37M | -26.88M | -32.16M | -28.61M | -2.14M | -13.47M | -9.23M | -9.69M | -8.40M | -900.00K | -4.50M | 0.00 | -100.00K | 200.00K | -100.00K | -310.00K | -450.00K | -360.00K | -640.00K | -1.07M | -1.00M | -870.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -5,015.87% | -21,992.17% | 0.00% | 0.00% | 490.74% | -1,295.40% | -74.28% | -226.37% | -1,315.92% | -1,128.17% | -54.62% | -2,269.84% | -288.76% | -94.34% | -431.78% | -1,548.94% | -11.01% | -150.94% | -354.67% | -234.03% | -186.67% | -11.11% | -109.76% | 0.00% | -3.45% | 9.52% | -11.63% | -96.88% | -59.21% | -30.25% | -100.00% | -297.22% | -169.49% | -4,350.00% |
| EPS | -1.18 | -11.97 | -10.19 | -23.32 | -30.92 | -12.65 | -3.53 | 20.00 | -52.59 | -18.55 | -142.30 | -929.93 | -3.16K | -1.72K | -16.04K | -16.76K | -10.13K | -13.75K | -17.67K | -1.59K | -10.75K | -7.65K | -11.36K | -10.87K | -1.13K | -5.90K | 0.00 | -209.21 | 720.00 | -0.01 | -0.02 | -0.03 | -0.02 | -0.04 | -0.07 | -0.06 | -0.06 |
| EPS Diluted | -1.18 | -11.97 | -10.19 | -23.32 | -30.92 | -12.65 | -3.53 | -28.00 | -52.59 | -18.55 | -142.30 | -929.93 | -3.16K | -1.72K | -16.04K | -16.76K | -10.13K | -13.75K | -17.67K | -1.57K | -10.75K | -7.65K | -11.36K | -10.87K | -1.13K | -5.90K | 0.00 | -209.21 | 640.00 | -0.01 | -0.02 | -0.03 | -0.02 | -0.04 | -0.07 | -0.06 | -0.06 |
| Weighted Avg Shares Out | 2.31M | 650.18K | 543.83K | 542.04K | 541.94K | 491.81K | 237.16K | 131.51K | 123.17K | 84.69K | 67.09K | 31.64K | 8.79K | 4.68K | 3.69K | 3.12K | 2.65K | 2.34K | 1.62K | 1.34K | 1.25K | 1.21K | 853.00 | 773.00 | 797.00 | 763.00 | 14.95K | 478.00 | 389.00 | 15.58M | 15.58M | 15.58M | 15.58M | 15.58M | 15.58M | 15.58M | 15.58M |
| Weighted Avg Shares Out (Dil) | 2.31M | 650.18K | 543.83K | 542.04K | 541.94K | 491.81K | 237.16K | 164.37K | 123.17K | 84.69K | 67.09K | 31.64K | 8.79K | 4.68K | 3.69K | 3.12K | 2.65K | 2.34K | 1.62K | 1.37K | 1.25K | 1.21K | 853.00 | 773.00 | 797.00 | 763.00 | 14.95K | 478.00 | 389.00 | 15.58M | 15.58M | 15.58M | 15.58M | 15.58M | 15.58M | 15.58M | 15.58M |
Manufacturing Commences on Adhera's MLR-1019 for Phase 2a Clinical Trial Treating Parkinson's Disease
IP Estate Grows with New Korean Patent Issued
7 Biotech Penny Stocks With Huge Catalysts Coming in 2022
With a new year fast approaching, these biotech penny stocks may benefit from the shifting winds in the broader healthcare market. The post 7 Biotech Penny Stocks With Huge Catalysts Coming in 2022 appeared first on InvestorPlace.
Adhera Receives European Patent Covering MLR-1019 and Derivatives for Treating Dyskinesias
Baton Rouge, LA, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce that a new European patent has been issued for MLR-1019 (armesocarb), a drug...
Source: https://incomestatements.info
Category: Stock Reports